Clindamycin - SkyePharma

Drug Profile

Clindamycin - SkyePharma

Alternative Names: Clindamycin HIT formulation - SkyePharma; Clindamycin Hyaluronan Induced Targeting formulation - SkyePharma; Hyclinda

Latest Information Update: 17 Oct 2007

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Shire Pharmaceuticals Group; SkyePharma Inc
  • Developer Pacira Pharmaceuticals
  • Class Antibacterials; Lincosamides; Small molecules
  • Mechanism of Action Protein 50S ribosomal subunit inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Acne

Most Recent Events

  • 31 Jul 2002 Hyclinda(TM) is available for licensing []
  • 07 Jun 2002 Phase-III clinical trials in Acne in United Kingdom (Topical)
  • 02 Oct 2001 No-Development-Reported for Acne in United Kingdom (Topical)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top